Zenyth Operations Pty. Ltd.

Csl Limited

Felicity Meredith Dunlop

Manuel Baca

Andrew Donald Nash

Louis Jerry Fabri

Douglas James Hilton

Nicos Anthony Nicola

Con Panousis

Matthew Hardy

Kirsten Edwards

Arna Elizabeth Andrews

Pierre David Scotney

Kirsten Mae Edwards

Matthew Philip Hardy

The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor.

Nucleic acids encoding antibodies against human granulocyte-colony stimulating factor receptor (G-CSFR) and method of expressing encoded protein

Antibodies against G-CSFR and uses thereof

The present invention relates generally to the field of cancer therapy and prophylaxis. More particularly, the present invention provides growth factor antagonists which inhibit the growth of cancers including tumors and pre-cancerous tissue. Even more particularly, the present invention is directed to antagonists of vascular endothelial growth factor-B and their use to inhibit the growth of cancer including tumor tissue and pre-cancerous tissue.

Method of treating cancer comprising a VEGF-B antagonist

The present invention relates generally to antibodies that bind to the Interleukin-13 receptor.alpha.1 chain (IL-13R.alpha.1) and antagonize IL-13 receptor-mediated signaling by IL-13 and/or IL-4. More particularly, the present invention provides humanized or human antibodies to mammalian and in particular IL-13R.alpha.1. These antibodies have uses in the treatment or prevention of IL-13- and/or IL-4-mediated diseases or conditions. The present invention further contemplates a method of modulating IL-13- and/or IL-4-mediated diseases or conditions by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies or other agents which modulate IL-13 and/or IL-4 signaling through an IL-13 receptor complex. Accordingly, a method of screening for modulators of IL-13R.alpha.1/ligand interaction is also provided.

Monoclonal antibody against interleukin-13 receptor alpha 1 (IL-13Ralpha1)

The present invention relates generally to antibodies that bind to the Interleukin-13 receptor &#x3b1;1 chain (IL-13R&#x3b1;1) and antagonize IL-13 receptor-mediated signaling by IL-13 and/or IL-4. More particularly, the present invention provides humanized or human antibodies to mammalian and in particular IL-13R&#x3b1;1. These antibodies have uses in the treatment or prevention of IL-13- and/or IL-4-mediated diseases or conditions. The present invention further contemplates a method of modulating IL-13- and/or IL-4-mediated diseases or conditions by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies or other agents which modulate IL-13 and/or IL-4 signaling through an IL-13 receptor complex. Accordingly, a method of screening for modulators of IL-13R&#x3b1;1/ligand interaction is also provided.

Monoclonal antibody against interleukin-13 receptor alpha 1 (IL-13Ra1)

Growing community of inventors

Regent, Australia

Felicity Meredith Dunlop